The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

Acute leukemia arises from genetic alterations within hematopoietic cells, which lead to unregulated cellular proliferation. Scientists have detected rearrangements of the lysine methyltransferase 2A ...

Nuri Jeong remembers the feeling of surprise she felt during a trip back to South Korea, while visiting her grandmother, who'd been grappling with Alzheimer's disease. "I hadn't seen her in six years, ...

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns ...

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

SUDO-550 demonstrated favorable safety, tolerability, and once-daily pharmacokinetic profile with full central nervous system (CNS) penetration - Achieved exposure levels associated with >90% ...

A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...